Skip to content
Head to head

Rhythm Pharmaceuticals vs Vertex Pharmaceuticals

Side-by-side on the measures that matter, with a plain-English read. Full detail: RYTM · VRTX

Updated 8 minutes ago

1-year performance, rebased to 100

RYTM +11.6%VRTX +18.7%
Vertex Pharmaceuticals edges it on the scoreable measures. Vertex Pharmaceuticals has the highest Quant Rating (68); Vertex Pharmaceuticals has done best over the past year (+22%); Vertex Pharmaceuticals earns the most per share.
RYTMVRTX
Snapshot
Sector--Biotechnology
Last price112.36515.02
Change today-3.80%-1.08%
1-year return+11.6%+22.0%
Market cap$7.79B$130.58B
52-week range74.50 – 122.20412.27 – 568.67
Valuation
P/E (TTM)-38.6133.14
P/E percentile, own 5-yr range0th99th
P/B88.546.25
Dividend yield0.00%0.00%
Profitability & growth
EPS (TTM)-3.1115.32
Net profit (TTM)$-215.62M$3.88B
Revenue (TTM)$280.75M$12.95B
Provider revenue period date2026-09-292026-09-29
Revenue growth (YoY)+79.6%+11.8%
Gross margin88.2%85.5%
Operating margin-66.7%33.1%
Net margin-70.6%30.7%
Free cash flow (TTM)$-83.24M$3.20B
Provider cash-flow period date2026-09-292026-09-29
Ownership & sentiment
Institutional ownership116.1%96.8%
Insider activity (12mo)28 buy / 22 sell28 buy / 22 sell
Short interest (% of float)17.0%1.9%
Analyst consensus93% buy / 7% hold (15)95% buy / 5% hold (21)
Analyst price target$150 (+33%)$624 (+21%)
StockVane view
StockVane Quant RatingC (51)C (68)
Company
Employees4146,400
Founded20081989

▲ marks the more favourable stock(s) on measures with a clear direction (lower P/E, higher yield, higher Quant Rating, better 1-year return). Analyst consensus counts each covering institution once, at its most recent rating. Not a recommendation. Quant Rating method: Data & Methodology.